Literature DB >> 2668964

Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?

M Corominas1, H Kamino, J Leon, A Pellicer.   

Abstract

In vitro DNA amplification followed by oligonucleotide mismatch hybridization was used to study the frequency of HRAS mutations in the benign self-regressing skin tumors keratoacanthomas and in squamous cell carcinomas. We used freshly obtained keratoacanthomas as well as Formalin-fixed paraffin-embedded tissues from both types of tumors. DNA from 50 samples of each tumor type was analyzed for activating mutations involving codons 12 and 61. A relatively high percentage (30%) of HRAS mutations was found in the keratoacanthomas compared with 13% in the squamous cell carcinomas. The most frequent mutation identified is the A-T-to-T.A transversion in the second position of codon 61. The present findings demonstrate the involvement of the HRAS oncogene in human benign tumors. Moreover, they indicate that an activated HRAS oncogene is not sufficient to maintain a neoplastic phenotype and argue against a role of HRAS in the progression of skin tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668964      PMCID: PMC297841          DOI: 10.1073/pnas.86.16.6372

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

2.  Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture.

Authors:  H E Ruley
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

3.  Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene.

Authors:  Y Yuasa; S K Srivastava; C Y Dunn; J S Rhim; E P Reddy; S A Aaronson
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

4.  Mutations of the Kirsten-ras proto-oncogene in human preleukaemia.

Authors:  E Liu; B Hjelle; R Morgan; F Hecht; J M Bishop
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

5.  The spontaneous regression of keratoacanthoma in man.

Authors:  C G Ramselaar; J B van der Meer
Journal:  Acta Derm Venereol       Date:  1976       Impact factor: 4.437

6.  A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient.

Authors:  M H Kraus; Y Yuasa; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas.

Authors:  A Balmain; M Ramsden; G T Bowden; J Smith
Journal:  Nature       Date:  1984 Feb 16-22       Impact factor: 49.962

8.  Altered growth and differentiation of cultured mouse epidermal cells infected with oncogenic retrovirus: contrasting effects of viruses and chemicals.

Authors:  S H Yuspa; W Vass; E Scolnick
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

9.  alpha 1-antitrypsin deficiency detection by direct analysis of the mutation in the gene.

Authors:  V J Kidd; R B Wallace; K Itakura; S L Woo
Journal:  Nature       Date:  1983 Jul 21-27       Impact factor: 49.962

10.  Three different activated ras genes in mouse tumours; evidence for oncogene activation during progression of a mouse lymphoma.

Authors:  K H Vousden; C J Marshall
Journal:  EMBO J       Date:  1984-04       Impact factor: 11.598

View more
  13 in total

1.  Microsatellite instability and loss of heterozygosity in human pterygia.

Authors:  D A Spandidos; G Sourvinos; H Kiaris; J Tsamparlakis
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

3.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Authors:  Patrick A Oberholzer; Damien Kee; Piotr Dziunycz; Antje Sucker; Nyam Kamsukom; Robert Jones; Christine Roden; Clinton J Chalk; Kristin Ardlie; Emanuele Palescandolo; Adriano Piris; Laura E MacConaill; Caroline Robert; Günther F L Hofbauer; Grant A McArthur; Dirk Schadendorf; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

4.  Development of keratoacanthomas and squamous cell carcinomas in transgenic rabbits with targeted expression of EJras oncogene in epidermis.

Authors:  X Peng; J W Griffith; R Han; C M Lang; J W Kreider
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 5.  Biological challenges of BRAF inhibitor therapy.

Authors:  Igor Puzanov; Patrick Burnett; Keith T Flaherty
Journal:  Mol Oncol       Date:  2011-02-16       Impact factor: 6.603

6.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

7.  Pathways of tumor development and progression in drug-induced nonmelanoma skin cancer: a new hope or the next great confusion?

Authors:  Georgi Tchernev; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2014-04-11

8.  Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis.

Authors:  N R Soman; G N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral.

Authors:  K Osei-Sarfo; L Martello; S Ibrahim; A Pellicer
Journal:  Oncogene       Date:  2011-03-28       Impact factor: 9.867

Review 10.  ras activation in human tumors and in animal model systems.

Authors:  M Corominas; S R Sloan; J Leon; H Kamino; E W Newcomb; A Pellicer
Journal:  Environ Health Perspect       Date:  1991-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.